Artrya Limited ( (AU:AYA) ) has shared an update.
Artrya Limited has secured a significant commercial contract with Lumus Imaging for the use of its Salix® Coronary Anatomy platform, marking a major step in its commercial growth in Australia. This 36-month agreement will see the integration of Artrya’s AI-driven technology at Lumus Imaging’s St George centre in New South Wales, utilizing the advanced Photon Counting CT scanner to enhance cardiovascular disease diagnosis. The collaboration is expected to generate revenue through a SaaS subscription model and reinforces Lumus Imaging’s commitment to cutting-edge innovation in patient care.
More about Artrya Limited
Artrya Limited, based in Perth, Australia, is an applied artificial intelligence healthcare company founded in 2018. The company focuses on improving the diagnosis of coronary heart disease using deep-learning algorithms and aims to develop a comprehensive overview of at-risk patients. Artrya was listed on the Australian Securities Exchange in 2021 and is working towards regulatory approval for its technology in the US.
YTD Price Performance: 64.15%
Average Trading Volume: 248,213
Technical Sentiment Signal: Sell
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.